We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cadence to Resubmit Ofirmev NDA Following Meeting With the FDA
Cadence to Resubmit Ofirmev NDA Following Meeting With the FDA
April 23, 2010
Cadence Pharmaceuticals plans to resubmit an NDA within 30 days for its pain treatment Ofirmev, the company’s only investigational product candidate, based on a recent meeting with the FDA.